Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
Aspire Biopharma (Nasdaq: ASBP) filed an omnibus patent application with the U.S. Patent and Trademark Office on October 6, 2025, seeking broad protection for its sublingual drug delivery platform.
The application targets multiple drug classes and aims to protect features that increase API bioavailability and speed of onset via rapid sublingual absorption, bypassing first-pass metabolism, reducing GI exposure and interactions, and improving ease of administration in emergency settings. Aspire says the omnibus filing complements patents already filed and expands its intellectual property coverage across new product areas.
Aspire Biopharma (Nasdaq: ASBP) ha presentato una domanda omnibus di brevetto presso l'U.S. Patent and Trademark Office il 6 ottobre 2025, chiedendo una protezione ampia per la sua piattaforma di somministrazione di farmaci sublinguale.
L'applicazione mira a diverse classi di farmaci e punta a proteggere caratteristiche che aumentano la biodisponibilità dell'API e la rapidità di inizio dell'azione tramite un rapido assorbimento sottolinguale, bypassando il metabolismo di primo passaggio, riducendo l'esposizione GI e le interazioni, e migliorando la facilità di somministrazione in contesti d'emergenza. Aspire afferma che la domanda omnibus integra i brevetti già depositati ed estende la copertura della proprietà intellettuale in nuove aree di prodotto.
Aspire Biopharma (Nasdaq: ASBP) presentó una solicitud de patente omnibus ante la Oficina de Patentes y Marcas de EE. UU. el 6 de octubre de 2025, buscando una protección amplia para su plataforma de administración de fármacos sublingual.
La solicitud apunta a múltiples clases de fármacos y tiene como objetivo proteger características que aumenten la biodisponibilidad de la API y la rapidez de inicio mediante una absorción sublingual rápida, evitando el metabolismo de primer paso, reduciendo la exposición gastrointestinal y las interacciones, y mejorando la facilidad de administración en entornos de emergencia. Aspire afirma que la presentación omnibus complementa a las patentes ya presentadas y amplía su cobertura de propiedad intelectual en nuevas áreas de producto.
Aspire Biopharma (Nasdaq: ASBP)가 2025년 10월 6일 미국 특허청(USPTO)에 omnibus 특허 출원을 제출하여 서브링구얼 약물 전달 플랫폼에 대한 광범위한 보호를 추구했습니다.
출원은 여러 약물 계통을 대상으로 하며, 빠른 서브링구얼 흡수를 통한 API 생체이용률과 발현 속도를 높이고, 최초 경로 대사를 우회하며, GI 노출과 상호작용을 감소시키고, 응급 상황에서의 투약 용이성을 개선하는 특징들을 보호하는 것을 목표로 합니다. Aspire는 omnibus 출원이 이미 제기된 특허를 보완하고 새로운 제품 영역에서 지적 재산권 커버리지를 확장한다고 말합니다.
Aspire Biopharma (Nasdaq : ASBP) a déposé une demande de brevet omnibus auprès de l'Office américain des brevets et des marques (USPTO) le 6 octobre 2025, sollicitant une protection étendue pour sa plateforme d'administration de médicaments sublinguale.
La demande vise plusieurs classes de médicaments et cherche à protéger des caractéristiques qui augmentent la biodisponibilité de l'API et la vitesse d'apparition via une absorption sublinguale rapide, en contournant le métabolisme de premier passage, en réduisant l'exposition gastro-intestinale et les interactions, et en améliorant la facilité d'administration en situations d'urgence. Aspire indique que le dépôt omnibus complète les brevets déjà déposés et étend sa couverture de propriété intellectuelle dans de nouveaux domaines de produits.
Aspire Biopharma (Nasdaq: ASBP) hat am 6. Oktober 2025 beim US-Patent and Trademark Office eine Omnibus-Patentanmeldung eingereicht und schützt eine breite Plattform für die sublinguale Verabreichung von Medikamenten.
Die Anmeldung richtet sich an mehrere Arzneimittelklassen und zielt darauf ab, Merkmale zu schützen, die die Bioverfügbarkeit der API und die Anlaufgeschwindigkeit durch eine schnelle sublinguale Absorption erhöhen, indem der First-Pass-Metabolismus umgangen, die GI-Exposition und Interaktionen reduziert und die Verabreichung in Notfällen erleichtert wird. Aspire erklärt, dass die Omnibus-Anmeldung Patente ergänzt, die bereits eingereicht wurden, und ihren IP-Schutz in neuen Produktbereichen erweitert.
Aspire Biopharma (Nasdaq: ASBP) قدمت طلب براءة omnibus لدى مكتب براءات الاختراع والعلامات التجارية الأمريكي في 6 أكتوبر 2025، تسعى لحماية واسعة لمنصة توصيل الدواء تحت اللسان.
يستهدف الطلب عدة فئات من الأدوية ويهدف إلى حماية السمات التي تزيد من التوافر الحيوي لمادة API وسرعة بدء العمل من خلال امتصاص تحت اللسان السريع، مع تجاوز أيض الطريق الأول، وتقليل التعرض للجهاز الهضمي والتفاعلات، وتحسين سهولة الإعطاء في إعدادات الطوارئ. تقول Aspire إن تقديم omnibus يكمل براءات سبق تقديمها ويوسع تغطية الملكية الفكرية لديها عبر مجالات منتجة جديدة.
Aspire Biopharma（Nasdaq: ASBP） 于 2025 年 10 月 6 日向美国专利商标局提交了一份 omnibus 专利申请，寻求对其舌下给药平台的广泛保护。
该申请面向多种药物类别，旨在通过快速舌下吸收提高 API 的生物利用度和起效速度，绕过首过效应，降低对胃肠道的暴露和相互作用，并在紧急情境下提高给药便利性。Aspire 表示 omnibus 提交补充了已提交的专利，并在新产品领域扩大其知识产权覆盖范围。
- Filed omnibus patent application with USPTO on Oct 6, 2025
- Platform designed to increase bioavailability and speed of onset
- Omnibus filing expands IP beyond patents already filed
- Application is patent pending and provides no enforceable patent rights until grant
Insights
Filing a broad omnibus patent application signals IP expansion but offers uncertain near-term commercial upside.
Aspire Biopharma has filed an omnibus patent application with the U.S. Patent and Trademark Office on
The business impact depends on claim allowance and scope; patent prosecution can narrow claims and take years. Granting could strengthen exclusivity and licensing potential, but the press release contains no prosecution timeline, allowed claims, or commercialization milestones, so near-term commercial effects remain unproven.
Watch USPTO prosecution progress, issued claims, and any subsequent patent grants or licensed agreements as the primary signals. Also monitor any product-specific filings or regulatory steps that tie the platform to concrete drug candidates; those items will clarify commercial value over the medium term.
ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application - which seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances--focuses exclusively on protecting the Company's advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients ("APIs") and other substances into the bloodstream, increasing bioavailability and improving speed of onset.
An omnibus claim is a statement in a patent application that describes the unique features of an invention and defines the scope of protection for the patent. It is a formal way of summarizing the points of novelty of the invention and is usually followed by a fixed form. The omnibus patent can provide IP protection in new areas/classes in addition to the patents already filed by Aspire.
The Aspire sublingual delivery platform represents a significant advancement in drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredients (APIs) and addressing critical challenges in both local and systemic drug delivery. The omnibus patent application underscores Aspire's commitment to securing comprehensive intellectual property protection for its innovative technology in a variety of product areas beyond the patents already filed, which aims to revolutionize sublingual drug delivery.
Key Features of Aspire's Sublingual Drug Delivery Platform
Rapid absorption through sublingual blood vessels directly, bypassing first-pass metabolic processes
Faster onset of action
Sublingual route avoids exposing the drug to the harsh acidic environment of the stomach and GI tract
Reduced drug-food and drug-drug interactions
Lower risk of GI irritation
Ease of administration and use in emergency situations
"The filing of this omnibus patent application for our sublingual delivery platform marks another important step in strengthening our intellectual property portfolio among many classes of drugs. We believe our technology has the potential to transform sublingual drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes," said Kraig Higginson, Interim Chief Executive Officer of Aspire.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.
For more information, please visit www.aspirebiolabs.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Aspire Biopharma (ASBP) announce on October 6, 2025?
What does Aspire's omnibus patent application for ASBP cover?
How does Aspire say the sublingual platform (ASBP) improves drug performance?
Does the ASBP omnibus filing create immediate patent rights?
Will the ASBP omnibus patent replace Aspire's existing patents?
